Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If the claim is they obtained a drug illegally, administered the drug, it had a miraculous effect not supported by data, and the story is tied to a notorious “promoter” who happened to get it directly from the CEO?
Yeah. I want to see some documentation.
How so? Please provide documentation that the miracle child received leronlifail and recovered solely because of it.
How would she know her son received treatment?
Leronlifail isn’t approved for compassionate use. Nader can’t just walk up to her and her a dose.
If it were part of the trial, how would she know her son received the drug?
The whole story is bullsh*t. It was a desperate PR stunt to pump a sinking share price.
That’s patently untrue. It’s not a primary metric, but placebo can exist in any population group, with diminishing effect as condition worsens.
LL hasn’t passed a trial yet, only a tiny subgroup cobbled together to salvage the disaster.
Also, the miracle child received Leronlifail directly from Nader? Under what permission in the US?
It’s funny these mythical stories are light on details. CYDY has crossed over into religious territory.
Trials proved it didn’t work.
You know, the ones that drugs have to pass because you can’t just make up bullsh*t stories.
Again, not short. The fact you won’t believe that, but will accept a resurrection with no evidence speaks volumes.
Doesn’t matter though. There was no sick son who only lived due to Leronlifail.
Cydy has failed in every conceivable way.
I don’t short OTC companies. Ridiculous margin requirements, and crazy cultists can drive the price in crazy ways.
Having said that, there was no miraculous healing caused by Leronlifail. None.
And literally nothing about that story undoes the lies, failed promises, failed trials, and significant cash flow deficiencies.
Lol, the fiction you continue to conjure is just sad.
Failed trials. Imaginary deals. Fictional miraculous healings.
Drama is the only product this company produces.
Prayer would do just as well as leronlifail in actual scientific trials.
They both fail. Miserably.
Is that why relative improvement TO PLACEBO is a key metric for trials, even for Covid?
Placebo occurs in all situations to some extent, no matter how small.
Leronlifail is no better than placebo.
He had been exposed multiple times over, as has CYDY, as has the impotence of leronlifail.
The fact anyone is supposedly hoping for leronlifail to be a miracle drug “yet again” is pure tragedy. Of course, one can’t validate such miraculous claims, as always.
What can be verified is the criminal handling of CYDY and felonious history of its chief executive.
You still have absolutely no reason to be this bearish.
No data, no reasoning outside your own absurd extrapolations.
What I find interesting is how your language is starting to hedge on the positive.
Another comical bear with only the voices in his head to keep him company.
Yeah, keep hoping it'll track between 15 and 20 for the next few months, but it's starting to break out. We'll see if it actually holds above 20.
Given this latest miserable pump attempt, I’d hope the SEC would intervene.
Bottom of the barrel stuff at this point.
The science was studied. It failed its trial miserably.
Insiderfinancial is a pump rag.
More bullsh*t.
NIH trial has never been a part of the EUA application. It has ALWAYS been the data catalyst for BLA.
It means Remdisivir has been shown to be completely needless across multiple Activ arms.
Now, I’ll summarize what certain people will say:
“See? No market for Lenz. No EUA. I’m an idiot”.
“See? This is why insiders are selling. I’m an idiot.”
This confirms what another person who spoke to IR said recently.
If it’s another 11 million shares, then we’d better have the volume!
We actually agree on this point, which is why I caution people not to try and divine hidden meaning from routine preparatory actions.
The update is mildly interesting, but not unexpected. Once EUA is given, the site needs to already be in place.
Sure, if you want to extrapolate something that isn’t there.
No one coordinated options off of an unpublished link that may or may not have any meaning.
What we did do is avoid making a big deal out of something that was vague at best.
If people are now going crazy because of that site, then they’re bigger morons than I thought. The evidence for lenzilumab has been overwhelming for some time already.
1) No one was supposed to know about it, because it wasn't meant to be live yet.
2) It causes rampant speculation, something that the few who knew about it refrained from engaging in, as it could simply be a placeholder and mean nothing right now.
Because words like “recommendation” have much different meaning from layman usage.
A recommendation has to be made based on milestones. Activ-5 isn’t done, so NIH can’t make a recommendation. They did make a note of Lenzilumab’s effectiveness, but until that trial concludes, there’s no recommendation.
Now we can blame big pharma or politics all day about why it’s not done, but it’s little more than sophistry without hard evidence.
GM-CSF inhibitors have had mixed results; Lenzilumab is a unique case where the dosage is high enough to be effective while also safe enough to be taken at that dosage due to its formulation.
Lenzilumab will be given an EUA and become part of the SOC.
The only reference I found to a 60-day time limit is in response to a fast-track designation.
Oh, and it’s odd that you don’t seem to follow HGEN’s guidance on manufacturing given they’ve been accurate thus far.
100k minimum in 2021, larger capacity next year with Car-T becoming a greater focus.
Next.
No, price targets have consistently been $25-40, with price raises or confirms over the last couple of months.
Korean trials will be successful. You have no evidence they will fail given how successful we’ve been to this point.
Sorry, bashing a biotech for not producing revenue, when all indications have been positive to this point, is bizarre. In fact, your negative fascination with Humanigen specifically is bizarre given the number of obviously garbage biotechs that exist.
You’ve been wrong about the company’s direction so far, and you’ll continue to be wrong in the future.
Estimates aren’t going down.
First product is in the verge of revenue production.
“Heavy insider selling” is now defined as preplanned sales of 20% apparently.
Oh, and our trial for import into South Korea has now been approved, another revenue vector in 2022.
Phase 3 successful.
UK requested we apply for expedited approval, which has been accepted.
Your inability to face reality is now legendary.
Yep, always good to get a fresh shot of hopium and delusion.
Makes bag-holding much easier.
Buy HGEN shares. Hold.
If you have to go lottos, August options. However, premiums are terrible.
Just buy the shares.
We had a similar contest between HGEN and GME when both were around 5-10 dollars that lasted for quite a while.
Guess which won? Lol.
Nomis is selling.
Dale’s fund is selling.
If that old info is bothering you, then sell.
There’s literally nothing new to discuss outside of more confirmation that lenzilumab will be approved in the UK, and will likely receive an EUA by the end of July.
You’re certainly welcome to sell if you believe that narrative.
Yep. This will be my post-HGEN stock (after the mega boom)!
Be careful of speculative growth tech right now, but long-term I like $100+.
Leronlimab is revenue-agnostic.
It’s also successful trial-agnostic.
CYDY has a rabid moronic cultish retail base. Their market cap is driven purely by lies and hopium. It’s completely divorced from reality; it’s also about to get flushed hard.
There’s no comparison between these two companies.
There’s no game. mITT was more appropriately selective, as the criterion was patients observed by someone qualified to be served a full treatment.
We were even more effective with no exclusion, or ITT, precisely the opposite of what STATNews and other bears were implying would happen (1.54 vs 1.9 HR).
So, we reported the more correct result to our own detriment, because it was proper to do so (and was still stat sig with primary endpoint met).
Other “biotech” companies would have done the opposite *cough* cydy *cough*
The full context was then presented later, I'm sure in part due to the pushback they received for originally posting the mITT.
Thanks for the documents.
What game with our hazard ratio are you specifically referencing?
I couldn’t verify the June 30th date specifically, not the paperwork specifying shares to be sold.